KR940021068A - 항종양 미토크산트론 중합체 조성물 - Google Patents

항종양 미토크산트론 중합체 조성물 Download PDF

Info

Publication number
KR940021068A
KR940021068A KR1019940005977A KR19940005977A KR940021068A KR 940021068 A KR940021068 A KR 940021068A KR 1019940005977 A KR1019940005977 A KR 1019940005977A KR 19940005977 A KR19940005977 A KR 19940005977A KR 940021068 A KR940021068 A KR 940021068A
Authority
KR
South Korea
Prior art keywords
compound
copolymer component
anthracene
synthetic
pharmaceutical composition
Prior art date
Application number
KR1019940005977A
Other languages
English (en)
Other versions
KR100348380B1 (ko
Inventor
초우 후웨이-루
Original Assignee
알퐁스 아아르 노에
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알퐁스 아아르 노에, 아메리칸 사이아나밋드 캄파니 filed Critical 알퐁스 아아르 노에
Publication of KR940021068A publication Critical patent/KR940021068A/ko
Application granted granted Critical
Publication of KR100348380B1 publication Critical patent/KR100348380B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

디비닐 에테르-무수말레인산 (MVE) 공중합체와 공유 결합되거나, 또는 상기 공중합체와 혼합된 안트라센 항종양 화합물, 특히 미토크산트론으로 구성된 항종양 종합체 조성물 및 상기 조성물을 투여함으로써, 포유류내 충실성 종양을 치료하고 백혈병 세포 생장의 퇴행을 유발시키는 방법.

Description

항종양 미토크산트론 중합체 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 P388종양 모델에 대해 본 발명의 미토크산트론-공중합체 조성물을 비교하여 유리 미토크산트론으로 치료된 생쥐의 수명 증가 퍼센트(% ILS)를 도해한 그래프이다.
제2도는 H207 생쥐 난소 종양 모델에 대해 본 발명의 미토크산트론-공중합체 조성물을 비교하여 유리 미토크산트론의 생체내 시험의 결과를 도해한 그래프이다.

Claims (10)

  1. 디비닐 에테르 및 무수말레인산의 공중합체 성분과 공유 결합되거나, 또는 상기 공중합체 성분과 혼합된 합성 안트라센 안티네오플라스틱 화합물과 제약학적으로 허용 가능한 부형제의 배합물로 구성된 제약학적 조성물.
  2. 하기 일반 구조식의 공중합체 성분으로 구성된 중합체 화합물 또는 이들의 제약학적으로 허용 가능한 염:
    상기식에서, n은 최소한 2의 정수이고, R은 질소와 함께 결합하여 공중합체 성분의 카르보닐 기와 아미드 결합을 형성할 수 있는 반응성 아미노 기를 갖는 합성 안트라센 안티네오플라스틱 화합물이다.
  3. 제1항에 있어서, 합성 안트라센 화합물이 미토크산트론 및 비산트렌으로 구성되는 군으로부터 선택되는 제약학적 조성물.
  4. 제1항에 있어서, 합성 안트라센 화합물이 미토크산트론이 제약학적 조성물.
  5. 제1,3 또는 4항에 있어서, 무수말레인산 및 디비닌 에테르의 공중합체 성분은 50,000 또는 그 미만의 분자량을 갖는 제약학적 조성물.
  6. 제2항에 있어서, 합성 안트라센 안티네오플라스틱 화합물이 미토크산트론인 중합체 화합물.
  7. 제6항에 있어서, 합성 안트라센 안티네오플라스틱 화합물이 미토크산트론인 중합체 화합물.
  8. 제1항에 따른 조성물의 치료학적 유효량을 포유류에게 투여하는 것으로 구성된 상기 포유류내 충실성 종양 치료 방법.
  9. 제1항에 따른 조성물의 치료학적 유효량을 포유류에게 투여하는 것으로 구성된 상기 포유류내 백혈병 세포 생장의 퇴행 유발 방법.
  10. 적당한 촉매의 존재하 유기 용매내에서 무수말레인산 및 디비닐 에테르의 공중합체와 합성 안트라센 안티네오플라스틱 화합물을 반응시키고 결과로서 얻은 생성물을 유리산 형태로 가수분해하는 것으로 구성되는, 하기 일반구조식의 공중합체 성분으로 구성된 중합체 화합물의 제조 방법. :
    상기식에서, n은 최소한 2의 정수이고, R은 질소와 함께 결합하여 공중합체 성분의 카르보닐 기와 아미드 결합을 형성할 수 있는 반응성 아미노 기를 갖는 합성 안트라센 안티네오플라스틱 화합물이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940005977A 1993-03-25 1994-03-24 항종양미토크산트론중합체조성물 KR100348380B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/037149 1993-03-25
US08/037,149 US5378456A (en) 1993-03-25 1993-03-25 Antitumor mitoxantrone polymeric compositions

Publications (2)

Publication Number Publication Date
KR940021068A true KR940021068A (ko) 1994-10-17
KR100348380B1 KR100348380B1 (ko) 2004-03-25

Family

ID=21892713

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940005977A KR100348380B1 (ko) 1993-03-25 1994-03-24 항종양미토크산트론중합체조성물

Country Status (11)

Country Link
US (1) US5378456A (ko)
EP (1) EP0616813B1 (ko)
JP (1) JPH06321927A (ko)
KR (1) KR100348380B1 (ko)
AT (1) ATE210996T1 (ko)
CA (1) CA2119675A1 (ko)
DE (1) DE69429468T2 (ko)
DK (1) DK0616813T3 (ko)
ES (1) ES2169049T3 (ko)
PT (1) PT616813E (ko)
SG (1) SG52340A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533467A (en) * 1993-07-19 2006-02-24 Angiotech Pharm Inc Anti-angiogenic compositions and methods of use
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5609867A (en) 1994-11-01 1997-03-11 American Cyanamid Company Polymeric antitumor agents
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
GB0123232D0 (en) * 2001-09-26 2001-11-21 Smith & Nephew Polymers
US7939054B2 (en) * 2006-10-27 2011-05-10 Giuseppe Trigiante Compositions for removing hair
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
EP4349325A1 (en) * 2021-05-28 2024-04-10 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182800A (en) * 1977-07-16 1980-01-08 Hercules Incorporated Methotrexate-divinyl ether--maleic anhydride copolymer reaction product
JPS6067490A (ja) * 1983-09-24 1985-04-17 Agency Of Ind Science & Technol アントラサイクリン系抗生物質誘導体及びその製造方法
JPS6067426A (ja) * 1983-09-24 1985-04-17 Agency Of Ind Science & Technol 低毒性制ガン剤
US4520162A (en) * 1983-09-24 1985-05-28 Director-General Of The Agency Of Industrial Science & Technology Polymeric compounds with sustained anti-tumor activity and a method for the preparation thereof
GB8413464D0 (en) * 1984-05-25 1984-07-04 Erba Farmitalia Anthracycline-anionic polymer conjugates
EP0265719B1 (en) * 1986-10-07 1991-03-06 Boehringer Mannheim Italia S.P.A. Pharmaceutical compositions having antineoplastic activity
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
JPH0762049B2 (ja) * 1991-03-18 1995-07-05 工業技術院長 高分子マイトマイシンｃ誘導体及びその製造方法
JP3069646B2 (ja) * 1991-05-28 2000-07-24 三共株式会社 ５−フルオロウリジン−高分子複合体

Also Published As

Publication number Publication date
DE69429468D1 (de) 2002-01-31
JPH06321927A (ja) 1994-11-22
DE69429468T2 (de) 2002-08-14
PT616813E (pt) 2002-06-28
KR100348380B1 (ko) 2004-03-25
DK0616813T3 (da) 2002-04-15
ATE210996T1 (de) 2002-01-15
EP0616813A2 (en) 1994-09-28
CA2119675A1 (en) 1994-09-26
US5378456A (en) 1995-01-03
ES2169049T3 (es) 2002-07-01
SG52340A1 (en) 1998-09-28
EP0616813B1 (en) 2001-12-19
EP0616813A3 (en) 1995-03-29

Similar Documents

Publication Publication Date Title
Maeda et al. Conjugation of poly (styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties
Maeda et al. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on smancs
Mahato Biomaterials for delivery and targeting of proteins and nucleic acids
Yokoyama et al. Analysis of micelle formation of an adriamycin-conjugated poly (ethylene glycol)–poly (aspartic acid) block copolymer by gel permeation chromatography
KR940003969A (ko) 피이지(peg)- 인터페론 결합체
KR940021068A (ko) 항종양 미토크산트론 중합체 조성물
FR2362119A1 (fr) Support polymere lie a un medicament cytotoxique
IL112920A (en) Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
EP0722971A3 (en) Biodegradable compositions of synthetic and natural polymers
MD1443G2 (ro) Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate
ATE123793T1 (de) Bindemittelzusammensetzung und deren verwendung in überzugsmitteln.
BR9805835A (pt) Mistura de poliamida e policetona
AU601960B2 (en) Dispersion polymers, processes for their preparation, and their use
KR930019220A (ko) 폴리하이드록시메틸렌 유도체를 함유하는 약제, 이의 제조방법 및 용도
RU2003127395A (ru) Содержащие пэг конъюгаты hgf-nk4
GR3006310T3 (ko)
DE60214354D1 (de) Verkettungsmittel und dieses enthaltende polyamidzusammensetzung
NL8600167A (nl) Polymeermengsel met polyfenyleenether en polyamide.
Schaefer et al. Properties of the interphase in ternary polymer composites
CA2033998A1 (en) Polyacetal copolymer and composition thereof
NO903119L (no) Katalysatorpreparater for anvendelse ved polymerisering.
UA42695C2 (uk) Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука
JPS6451476A (en) Moisture-curing binder composition and use
IT1250738B (it) Composizioni termoplastiche ad elevata tenacita' e resistenza all'urto
Lee et al. MMA/MPEOMA copolymers as coating materials for improved blood compatibility: protein adsorption study

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100630

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee